Rare‑Disease Makers Push for Medicare Price‑Cut Exemptions

Last week the Rare Disease Company Coalition— a loose alliance of biotech firms that focus on ultra‑rare conditions— headed to the West Wing for a sit‑down with the Office of Management and Budget. Their agenda? To ask the Trump administration to carve out a special exemption for orphan drugs from two Medicare pilot programs that are meant to force U.S. prices down to levels seen in other wealthy nations.

The pilots are part of what the administration calls a “most‑favored‑nation” strategy. In plain English, drug makers would have to price their brand‑name medicines for Medicare beneficiaries at or below the lowest price they charge in any of a list of select foreign markets. The idea is to bring down the bill for seniors, but critics say it could also squeeze the already‑thin margins that fund research into treatments for diseases that affect just a handful of patients.

During the meeting, coalition representatives emphasized that orphan drugs are fundamentally different from blockbuster therapies. They argued that the high cost of development—often running into the billions for a therapy that will serve only a few dozen patients—means that “price caps” could make many projects financially unviable.

What’s ironic, they noted, is that the pilots already exempt a number of the biggest pharmaceutical players. Companies like Pfizer, Roche and Novartis have secured waivers because their flagship drugs already fall under existing international price‑comparison schemes. The coalition fears that extending the exemption to rare‑disease products would further shrink the pool of drugs the pilots actually affect.

Supporters of the pilots, including several lawmakers and patient‑advocacy groups, counter that without strong price‑control mechanisms, Medicare’s drug spend will keep spiralling. They point to recent years where the Medicare Part D program has shouldered a growing share of the nation’s prescription‑drug burden, and argue that any loophole— even for orphan drugs— risks undermining the whole effort.

For now, the discussion is still ongoing. The White House has not yet signaled whether it will grant the requested exemption, but the coalition plans to keep the pressure on, warning that an overly aggressive price‑cut regime could “kill the pipeline for life‑saving treatments that patients with rare diseases desperately need.”

Both sides agree on one point: the stakes are high. Medicare’s budget, the financial health of biotech innovators, and, most importantly, the hope of patients living with conditions that affect fewer than 200,000 Americans are all on the line.